{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:17:26Z","timestamp":1791778646606,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.cca.2009.10.007","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T08:24:09Z","timestamp":1256286249000},"page":"140-146","source":"Crossref","is-referenced-by-count":65,"title":["Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS\/MS"],"prefix":"10.1016","volume":"411","author":[{"given":"Olivia","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Spreux-Varoquaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Bouchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Castaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Raggueneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Therond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maneglier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2009.10.007_bib1","first-page":"152","article-title":"Chronic myeloid leukemia in 2006: a perspective","volume":"91","author":"Mauro","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2009.10.007_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2009.10.007_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2009.10.007_bib4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Gibbons","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2009.10.007_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2009.10.007_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2009.10.007_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2009.10.007_bib8","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study","volume":"60","author":"Schmidli","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2009.10.007_bib10","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1200\/jco.2006.24.18_suppl.6119","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)","volume":"24","author":"Tsang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2009.10.007_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2009.10.007_bib12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2009.10.007_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib14","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.cca.2009.10.007_bib15","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.cca.2009.10.007_bib16","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2009.10.007_bib17","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Therapeutic drug monitoring in CML patients on imatinib","volume":"110","author":"Blasdel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2009.10.007_bib19","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib20","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.cca.2009.10.007_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jchromb.2003.10.025","article-title":"Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations","volume":"799","author":"Schleyer","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2009.10.007_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","article-title":"Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples","volume":"804","author":"Velpandian","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2009.10.007_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2004.01.006","article-title":"Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection","volume":"803","author":"Widmer","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2009.10.007_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/bmc.816","article-title":"Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography","volume":"21","author":"Oostendorp","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.cca.2009.10.007_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2009.10.007_bib27","doi-asserted-by":"crossref","unstructured":"Awidi A, Salem, II, Najib N, Mefleh R, Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: Methods' comparison. Leuk Res. in press, doi:10.1016\/j.leukres.2009.08.005.","DOI":"10.1016\/j.leukres.2009.08.005"},{"key":"10.1016\/j.cca.2009.10.007_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2009.10.007_bib29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/clinchem\/48.5.801","article-title":"Commentary on quantifying agreement between two methods of measurement","volume":"48","author":"Altman","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2009.10.007_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2009.10.007_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/clinchem\/39.3.424","article-title":"Evaluation of regression procedures for methods comparison studies","volume":"39","author":"Linnet","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2009.10.007_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/clinchem\/46.1.100","article-title":"General deming regression for estimating systematic bias and its confidence interval in method-comparison studies","volume":"46","author":"Martin","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2009.10.007_bib33","first-page":"162","article-title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment","volume":"91","author":"Colombat","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2009.10.007_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jpba.2008.07.018","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal part IV. Examples of application","volume":"48","author":"Hubert","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.cca.2009.10.007_bib35","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jms.1369","article-title":"Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry","volume":"43","author":"Rochat","year":"2008","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.cca.2009.10.007_bib36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib37","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2003-05-1629","article-title":"Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels","volume":"102","author":"Gambacorti-Passerini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cca.2009.10.007_bib38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","article-title":"Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia","volume":"89","author":"Kawaguchi","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cca.2009.10.007_bib39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2009.10.007_bib40","first-page":"379","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time","volume":"55","author":"Judson","year":"2005","journal-title":"EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2009.10.007_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1200\/JCO.2007.14.5110","article-title":"Imatinib for patients with liver or kidney dysfunction: no need to modify the dose","volume":"26","author":"Judson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2009.10.007_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cca.2009.03.042","article-title":"Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma","volume":"404","author":"Blanchet","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2009.10.007_bib43","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2009.10.007_bib44","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2009.10.007_bib45","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898109005348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898109005348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T06:26:11Z","timestamp":1590215171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898109005348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":45,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0009898109005348"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2009.10.007","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}